Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prednimustine treatment in malignant lymphomas.

I Szántó1, T Fleischmann, S Eckhardt

  • 1Department of Hematology, National Institute of Oncology, Budapest, Hungary.

Oncology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ESMO open·2025
Same author

Anthropogenic Impacts on Coral-Algal Interactions of the Subtropical Lagoonal Reef, Norfolk Island.

Integrative organismal biology (Oxford, England)·2025
Same author

Knowledge and management of traumatic dental injuries among schoolteachers in Hungary: a cross-sectional study with educational intervention.

European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry·2024
Same author

Neighbourhood species richness and drought-tolerance traits modulate tree growth and δ<sup>13</sup> C responses to drought.

Plant biology (Stuttgart, Germany)·2024
Same author

Non-pain-related complaints of paediatric patients after dental treatment under general anaesthesia.

European journal of paediatric dentistry·2023
Same author

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.

European journal of cancer (Oxford, England : 1990)·2023
Same journal

Real-World Outcomes in Acute Promyelocytic Leukemia: A 13-Year Cohort from Qatar.

Oncology·2026
Same journal

SF3A3 in Liver Hepatocellular Carcinoma: Oncogenic Role and Prognostic Significance.

Oncology·2026
Same journal

Letter to the Editor.

Oncology·2026
Same journal

FLAG-Based Versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Oncology·2026
Same journal

Longitudinal Changes in Body Weight and Body Mass Index in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Retrospective Observational Study.

Oncology·2026
Same journal

Rising lung cancer burden attributable to high fasting plasma glucose in women aged ≥50 years: age-, SDI-, and BRICS-specific patterns from GBD 1990-2021.

Oncology·2026
See all related articles

Prednimustine, a chlorambucil ester of prednisolone, shows efficacy in treating malignant lymphomas. Clinical trials observed partial remissions in patients with Hodgkin

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Prednimustine is a novel chlorambucil ester of prednisolone.
  • Malignant lymphomas represent a significant group of hematological malignancies.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of prednimustine (Stereocyt) in patients with malignant lymphomas.
  • To assess prednimustine's activity in refractory Hodgkin's disease, refractory non-Hodgkin lymphoma (NHL), and low-grade NHL as primary therapy.

Main Methods:

  • A clinical trial was conducted involving 25 patients diagnosed with malignant lymphomas.
  • Patients were stratified into three subgroups based on disease status: refractory Hodgkin's disease, refractory NHL, and low-grade NHL receiving primary therapy.
  • The efficacy and toxicity of prednimustine were monitored throughout the study.

Related Experiment Videos

Main Results:

  • Prednimustine demonstrated activity across all patient subgroups.
  • A total of 17 partial remissions were observed.
  • Mild and reversible leukopenia and thrombopenia were noted in 3 patients upon drug withdrawal.

Conclusions:

  • Prednimustine is an active agent in the treatment of malignant lymphomas.
  • The drug exhibits a favorable safety profile with manageable side effects.
  • Prednimustine shows promise as a therapeutic option for both refractory and newly diagnosed low-grade NHL.